寻常型天疱疮的靶向治疗:利妥昔单抗之外的新视野
寻常型天疱疮由抗桥粒芯蛋白3和1的致病性IgG自身抗体驱动,利妥昔单抗可使70-90%患者实现无治疗完全缓解,但约20-30%患者复发或无效。本文综述了五类新兴靶向治疗,包括新一代抗CD20单抗、BAFF/APRIL通路抑制剂、BTK抑制剂、FcRn拮抗剂和DSG3-CAAR T细胞疗法,并分析了其机制与临床证据。
要点
- 利妥昔单抗难治机制涉及B细胞再增殖、长寿命浆细胞、IgG4优势、FcγR信号及HACA形成。
- 新一代抗CD20单抗、BAFF/APRIL抑制剂和BTK抑制剂等五类靶向药正被评估。
- 部分III期试验未达主要终点,联合策略和优化试验设计对转化至关重要。
核心结论
- 多种新兴靶向治疗针对利妥昔单抗难治机制,但多数证据仍限于病例、队列或早期试验。
- 合理联合策略和优化试验设计是将生物学前景转化为临床实践的关键。
研究设计与样本
- 本文为综述, critically 评估了五类新兴靶向治疗寻常型天疱疮的机制与证据。
主要发现
- 利妥昔单抗可使70-90%患者实现无治疗完全缓解,但约20-30%患者复发或无效。
- 利妥昔单抗难治驱动因素包括BAFF/APRIL升高驱动的B细胞再增殖、骨髓龛长寿命浆细胞持续、IgG4优势自身抗体、Fcγ受体信号 innate 放大及人抗嵌合抗体形成。
- 新一代抗CD20单抗(ofatumumab、ocrelizumab、obinutuzumab、veltuzumab)提供增强效应功能、降低免疫原性和皮下给药,证据限于病例和队列水平。
- BAFF/APRIL通路抑制剂(telitacicept、ianalumab)在寻常型天疱疮病例报告和 extrapolated 系统性红斑狼疮2/3期数据中显示前景。
- BTK抑制剂rilzabrutinib在2期试验中显示快速疾病控制和有意义激素节约效应,但关键3期PEGASUS试验未达主要终点。
关键数值与推荐
- 利妥昔单抗完全缓解 off-therapy 率为70-90%,复发或无效率为20-30%。
- FcRn拮抗剂efgartigimod可在数周内使循环IgG降低60-70%,无广泛免疫抑制;3期ADDRESS试验未达主要终点,可能因皮质类固醇混杂而非生物学无效。
- DSG3-CAAR T细胞疗法可抗原特异性消除致病性抗Dsg3 B细胞,同时保留正常体液免疫,早期1期数据待公布。
临床怎么用
- 对利妥昔单抗难治或不耐受患者,可考虑新一代抗CD20单抗、BAFF/APRIL抑制剂等靶向治疗,但需认识证据局限性。
- BTK抑制剂和FcRn拮抗剂在部分试验中显示潜力,但III期结果阴性提示需优化患者选择和试验设计。
- DSG3-CAAR T细胞疗法代表最具变革性的方法,但尚处早期阶段。
局限性
- 多数新兴靶向治疗的证据限于病例报告、队列研究或早期试验,缺乏大规模随机对照数据。
- 部分关键III期试验(PEGASUS、ADDRESS)未达主要终点,存在皮质类固醇混杂等解释局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pemphigus vulgaris is a potentially life-threatening autoimmune blistering disorder driven by pathogenic IgG autoantibodies targeting desmoglein 3 and 1. While rituximab has transformed management-achieving complete remission off-therapy in 70-90% of patients-approximately 20-30% of patients relapse or fail to respond, defining a critical unmet need. The key drivers of rituximab-refractory disease include post-depletion B-cell repopulation fuelled by elevated BAFF and APRIL, persistence of long-lived plasma cells in bone marrow niches that evade anti-CD20 depletion, IgG4-dominant autoantibodies requiring high complement-dependent cytotoxicity, innate immune amplification via Fcγ-receptor signalling and human anti-chimeric antibody formation neutralizing the drug itself. This review critically evaluates five emerging targeted therapeutic classes addressing these mechanisms. Next-generation anti-CD20 monoclonal antibodies-ofatumumab, ocrelizumab, obinutuzumab and veltuzumab-offer enhanced effector functions, reduced immunogenicity and subcutaneous delivery for rituximab-intolerant or HACA-positive patients, though evidence remains at case and cohort level. BAFF/APRIL pathway inhibitors, principally telitacicept and ianalumab, target the B-cell survival axis elevated post-rituximab and show promise in pemphigus case reports and extrapolated phase 2/3 systemic lupus erythematosus data. Bruton tyrosine kinase inhibitors, particularly rilzabrutinib, demonstrated rapid disease control and meaningful steroid-sparing effects in phase 2 trials, though the pivotal PEGASUS phase 3 trial did not meet its primary endpoint. FcRn antagonists, led by efgartigimod, achieve 60-70% reduction in circulating IgG within weeks without broad immunosuppression; the phase 3 ADDRESS trial missed its primary endpoint, likely due to corticosteroid confounding rather than biological inefficacy. Finally, DSG3-CAAR T-cell therapy represents the most transformative approach-antigen-specific elimination of pathogenic anti-Dsg3 B cells while preserving normal humoral immunity-with early phase 1 data awaited. Rational combination strategies and refined trial designs will be essential to translate the biological promise of these next-generation agents into clinical practice for patients with refractory pemphigus.
引用
- Ahuja R, Murrell D. Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab. J Eur Acad Dermatol Venereol. 2026. PMID: 42836361. doi:10.1111/jdv.70773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。